<code id='CB53330FE6'></code><style id='CB53330FE6'></style>
    • <acronym id='CB53330FE6'></acronym>
      <center id='CB53330FE6'><center id='CB53330FE6'><tfoot id='CB53330FE6'></tfoot></center><abbr id='CB53330FE6'><dir id='CB53330FE6'><tfoot id='CB53330FE6'></tfoot><noframes id='CB53330FE6'>

    • <optgroup id='CB53330FE6'><strike id='CB53330FE6'><sup id='CB53330FE6'></sup></strike><code id='CB53330FE6'></code></optgroup>
        1. <b id='CB53330FE6'><label id='CB53330FE6'><select id='CB53330FE6'><dt id='CB53330FE6'><span id='CB53330FE6'></span></dt></select></label></b><u id='CB53330FE6'></u>
          <i id='CB53330FE6'><strike id='CB53330FE6'><tt id='CB53330FE6'><pre id='CB53330FE6'></pre></tt></strike></i>

          
          WSS
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion